These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 25746916)

  • 1. Clinical deployment of antibodies for treatment of melanoma.
    Curti BD; Urba WJ
    Mol Immunol; 2015 Oct; 67(2 Pt A):18-27. PubMed ID: 25746916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma.
    Matikas A; Mavroudis D
    Future Oncol; 2015; 11(6):997-1009. PubMed ID: 25760979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
    Simeone E; Ascierto PA
    J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.
    Kroon P; Gadiot J; Peeters M; Gasparini A; Deken MA; Yagita H; Verheij M; Borst J; Blank CU; Verbrugge I
    Cancer Immunol Immunother; 2016 Jun; 65(6):753-63. PubMed ID: 27160390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.
    Blank CU
    Curr Opin Oncol; 2014 Mar; 26(2):204-14. PubMed ID: 24424272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and Emerging Perspectives on Immunotherapy for Melanoma.
    Daud A
    Semin Oncol; 2015 Dec; 42 Suppl 3():S3-S11. PubMed ID: 26598057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
    Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
    J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
    Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
    Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
    [No Abstract]   [Full Text] [Related]  

  • 10. High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome.
    Dumitriu IE; Baruah P; Finlayson CJ; Loftus IM; Antunes RF; Lim P; Bunce N; Kaski JC
    Circ Res; 2012 Mar; 110(6):857-69. PubMed ID: 22282196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent Development of Therapies for Melanoma Using Immune Checkpoint Blockades].
    Okuyama R
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):661-5. PubMed ID: 27306802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Therapy in Melanoma.
    Callahan MK
    Cancer J; 2016; 22(2):73-80. PubMed ID: 27111901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma.
    Elia AR; Caputo S; Bellone M
    Front Immunol; 2018; 9():1786. PubMed ID: 30108594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
    Boutros C; Tarhini A; Routier E; Lambotte O; Ladurie FL; Carbonnel F; Izzeddine H; Marabelle A; Champiat S; Berdelou A; Lanoy E; Texier M; Libenciuc C; Eggermont AM; Soria JC; Mateus C; Robert C
    Nat Rev Clin Oncol; 2016 Aug; 13(8):473-86. PubMed ID: 27141885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of immunotherapy in the treatment of melanoma.
    Achkar T; Tarhini AA
    J Hematol Oncol; 2017 Apr; 10(1):88. PubMed ID: 28434398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint Blockade for the Treatment of Advanced Melanoma.
    Callahan MK; Flaherty CR; Postow MA
    Cancer Treat Res; 2016; 167():231-50. PubMed ID: 26601865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model.
    Padrón Á; Hurez V; Gupta HB; Clark CA; Pandeswara SL; Yuan B; Svatek RS; Turk MJ; Drerup JM; Li R; Curiel TJ
    Exp Gerontol; 2018 May; 105():146-154. PubMed ID: 29326088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor.
    Shindo Y; Yoshimura K; Kuramasu A; Watanabe Y; Ito H; Kondo T; Oga A; Ito H; Yoshino S; Hazama S; Tamada K; Yagita H; Oka M
    Anticancer Res; 2015 Jan; 35(1):129-36. PubMed ID: 25550543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.